Online investment management service Wealthsimple secured $74.6m in an Allianz X-led round that also featured long-standing investor Power Financial.

UCB Ventures and Alphabet unit GV took part in the RNA-targeting gene therapy developer's first publicly disclosed funding round, which was led by Arch Venture Partners.

The Bloomberg and Alphabet-backed CRM platform developer has boosted its series C round to $68m with a $15m extension.

Eli Lilly, WuXi Biologics and Alexandria-backed cancer and orphan disease therapy developer Inhibrx has received $40m in funding from Viking Global Investors.

With the growing focus on food sustainability, University of California (UC) Santa Barbara-founded food preservative developer Apeel Science is a particularly apt selection for the Technology of the Year award.

Of the strong candidates for GUV’s Deal of the Year, Lund and Edinburgh universities-founded drug developer Galecto Biotech sealed the award for a €79m ($90m) series C close that supplemented a promising set of clinical data for its lead candidate.

Deutsche Telekom and Access Industries contributed to a round that took the cloud and data centre security provider's overall funding to $108m.

Alphabet, Novartis and Johnson & Johnson have contributed to a series C round for Cala Health, which is preparing to release its wearable hand-tremor treatment device.

Lundbeckfond Ventures contributed to a round that will fund clinical trials for Reneo Pharmaceuticals' mitochondrial disease therapies.

Stanford-backed medical supplies delivery service Zipline has revealed two funding rounds totaling $190m, one of which is a $70m series C that included existing backer GV.